Exelixis, Inc. is a biopharmaceutical company. It engages in the developing and commercializing small molecule therapies for the treatment of cancer. The company brands include COMETRIQ and cobimetinib. It focuses on their proprietary resources and development and commercialization of cabozantinib. Exelixis was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.
